II. Epidemiology: Prevalence
- Most common Arrhythmia seen in adult primary care
- Affects 3 to 6 million adults in the United States
-
Prevalence increases with age (esp. age >50 years)
- Age 60 years: 1.5%
- Age 75 years: 9%
- Complications
- Primary cause of 30,000 to 40,000/year Cerebrovascular Accidents in the United States
III. Definitions
- Atrial Fibrillation
- Supraventricular Tachycardia with uncoordinated atrial activation and associated atrial contractile dysfunction
IV. Causes
- See Atrial Fibrillation Causes
- Atrial Fibrillation cause impacts risk of complications
- Valvular Atrial Fibrillation (e.g. mitral valve disorder) stroke risk: 17 fold increased risk
- Non-valvular Atrial Fibrillation stroke risk: 5 fold increased risk
V. Pathophysiology
- Mechanisms
- Enhanced automaticity at depolarizing foci
- Multiple small simultaneously wavelets arise and propagate
- May result from repeatedly firing Premature Atrial Contractions (PACs)
- Arise near origin of pulmonary veins at the left atrium
- Reentry via small aberrant circuits that spontaneously arise in atria
- Enhanced automaticity at depolarizing foci
- Initial Consequences: Acute Atrial Remodeling
- Patchy fibrosis
- Collagen deposition
- Sinoatrial Node fatty deposition
- Ion channel and depolarization changes
- Later Consequences: Chronic Atrial Remodeling
- Longterm Atrial Fibrillation results in atrial enlargement (irreversible)
- Possibility of restoring to normal sinus rhythm becomes less likely over time
- Functional Consequences: Atrial contractions are uncoordinated
- Rapid ventricular response
- Tachycardia and diminished diastolic filling decrease Cardiac Output
- Coronary circulation compromised and Cardiomyopathy increase morbidity and mortality
- Blood stasis and atrial clot forms
- Results in increased Thromboembolism and Cerebrovascular Accident risk
- Reduced Ventricular Filling (absent "Atrial Kick")
- Ventricular diastolic filling is primarily driven by a suction effect rather than atrial contraction
- However, with increased activity, the atrial contraction becomes more important to Cardiac Output
- Rapid ventricular response
VI. Types
- Acute Atrial Fibrillation
- New onset or recurrent Atrial Fibrillation lasting <48 hours
- Paroxysmal Atrial Fibrillation
- New or recurrent Atrial Fibrillation lasting <7 days and spontaneously resolves (self-terminates)
- Carries the same longterm CVA risk as persistent Atrial Fibrillation
- Persistent Atrial Fibrillation
- New or recurrent Atrial Fibrillation lasting >7 days and does not spontaneously resolve or self-terminate
- Results in cardiac remodeling (see above) and less likelihood overtime of restoring sinus rhythm
- Secondary Atrial Fibrillation
- Due to acute secondary cause
- Examples: MI, PE, Pericarditis, Myocarditis, Hyperthyroidism, Pneumonia
- Atrial Fibrillation expected to resolve after treatment of secondary cause
- Lone Atrial Fibrillation
- Atrial Fibrillation in age <60 years without underlying cardiopulmonary disease (associated with better prognosis)
-
Atrial Fibrillation with Rapid Ventricular Response (RVR)
- Heart Rate >100 beats/min at rest (or >110 beats/min on light activity)
-
Atrial Flutter
- See Atrial Flutter (includes 2 subtypes based on Atrial Flutter rate)
- Closely related to Atrial Fibrillation and often co-occurs in the same patient (even on the same EKG)
- Constant atrial rate, with a fixed ratio of A:V rate (1:1 of 300 bpm, 2:1 of 150 bpm, 3:1 of 90 bpm, 4:1 of 75 bpm)
- Treated identically to Atrial Fibrillation, but Atrial Flutter is easier to cardiovert and harder to rate control
VII. History
- Onset of current episode of Atrial Fibrillation
- Frequency of Atrial Fibrillation
- First episode
- Paroxysmal
- Persistent or chronic
- Precipitating factors or triggers of current episode
- See Atrial Fibrillation Causes
- Exacerbation of chronic disease
- Substances
- Alcohol Abuse (most common)
- Drug Abuse (Cocaine, Amphetamines)
- Caffeine
- Effective methods of terminating prior episodes
VIII. Symptoms
- Often asymptomatic (21% overall, and 50% in younger patients)
- Acute Fatigue
-
Palpitations (33% of cases)
- Abrupt onset and termination suggests supraventricular tachyarrhythmi
- Contrast with gradual onset of Sinus Tachycardia
- Associated with the irregular ventricular response
-
Angina or Chest Pain
- Suggests underlying Coronary Artery Disease or demand ischemia related to rapid ventricular rate
-
Dyspnea or Orthopnea
- May suggest underlying cardiac disease or secondary pulmonary cause (e.g. Pulmonary Embolism, COPD)
- Consider decompensation with Systolic Heart Failure (see below)
- Acute Congestive Heart Failure exacerbation
- Symptoms are related to decreased Cardiac Output (from loss of atrial kick or rapid ventricular rate)
-
Dizziness
- True Syncope (as opposed to Dizziness) is more often associated with ventricular Arrhythmia
- Findings of instability related to rapid ventricular rate (at very high rates)
IX. Signs: Cardiovascular
-
Pulse irregularly irregular
- Test Sensitivity: 92 to 94%
- Test Specificity: 72 to 82%
- Jugular Venous Pulsations irregular
- First Heart Sound may have variable amplitude
- Cardiac murmur may suggest underlying valvular heart disease
- Acute Congestive Heart Failure signs (e.g. rales, S3 gallup, Jugular Venous Distention)
X. Diagnostics
-
Electrocardiogram
- See Electrocardiogram in Atrial Fibrillation
- No discrete atrial activity (Discrete P Waves absent)
- Atrial Fibrillation waves (F Waves) seen as small irregular waves at rate >150/min
- Irregularly irregular ventricular rhythm
- Inconsistent R-R interval, with rates up to rapid rate up to 160-200 bpm in RVR
- Other rhythm evaluation in suspected paroxysmal Atrial Fibrillation
- Holter Monitor or Zio Monitor
- Event Monitor
- Loop recorders
- Wrist watches (Apple Watch)
- Evaluation for underlying Coronary Artery Disease if symptoms suggest (not typically the cause)
- Stress testing (e.g. Stress Echocardiogram, Stress Cardiolite)
XI. Labs (esp. for initial episode)
- Thyroid Function Test (TSH with reflex to T4 free)
- Chemistry panel with Electrolytes and Renal Function tests (basic metabolic panel)
- Complete Blood Count (CBC)
- Other tests that are not indicated unless specific findings
XII. Imaging
-
Chest XRay
- Assess for cardiac disease
- Cardiomegaly
- Congestive Heart Failure
- Assess for pulmonary disease
- Assess for cardiac disease
-
Transthoracic Echocardiogram (TEE if early cardioversion pursued)
- Indicated in all patients with new onset Atrial Fibrillation
- Assess left and right atrial size
- Assess ejection fraction
- Assess Left Ventricular Hypertrophy
- Observe for valvular disease
- Assess for Pulmonary Hypertension (peak RV pressure)
- May suggest Pulmonary Embolism or other pulmonary disease
XIII. Management: Acute
XIV. Management: Chronic
-
General measures
- Review Blood Pressures
- Consider stress testing (if specific indications as above)
- See Atrial Fibrillation Anticoagulation
- See Atrial Fibrillation Rate Control
- Reduce Atrial Fibrillation Risk Factors
- Medication Management (3 strategies)
- Atrial Fibrillation Rate Control (preferred in most cases)
- Preferred strategy over Atrial Fibrillation Rhythm Control
- Goal Heart Rate: <80 at rest (<110 during Exercise)
- Other strategies
- Efficacy
- Best chance of maintaining sinus rhythm is age <65 years with structurally normal heart
- Atrial Fibrillation Rate Control (preferred in most cases)
-
Atrial Fibrillation Ablation
- See Cardiac Catheter Ablation
- Consider for refractory and paroxysmal Atrial Fibrillation with increased morbidity on medication
- Effective at 2 years in 75% of cases
- Oral (2003) Circulation 108(19):2355-60 [PubMed]
- Invasive surgical procedures (higher risk)
- MAZE Procedure (open surgical procedure replaced in most cases by ablation as above)
- Left Atrial Appendage Closure Device (e.g. Watchman Device)
- Reduces stroke risk by removal or ligation of the left atrial appendage (source 90% of emboli)
- Decreases stroke risk, but does not affect underlying Atrial Fibrillation
- May be replaced in future by percutaneous placed LAA Occlusion devices (e.g. watchman, Amplatzer)
- Not approved for use in U.S. as of 2016
XV. Complications
- Congestive Heart Failure
- Myocardial Infarction
-
Cerebrovascular Accident
- Due to Thromboembolism
- Typically form in the left atrial appendage (hence LAA Obliteration procedure)
- Atrial Fibrillation is associated with a 5 fold increased CVA risk
- Risk increases with higher CHADS2-VASc Score
- Due to Thromboembolism
XVI. Prognosis
- Mortality: Increased up to two fold over the general population
XVII. References
- Casaletto (2014) Crit Dec Emerg Med 28(4): 10-19
- King (2002) Am Fam Physician 66(2):249-56 [PubMed]
- Gutierrez (2017) Am Fam Physician 83(1): 61-8 [PubMed]
- Gutierrez (2011) Am Fam Physician 94(6): 442-52 [PubMed]
- Holder (2024) Am Fam Physician 109(5): 398-404 [PubMed]
- Stiell (2011) Canadian J Cardiol 27(1): 38-46 [PubMed]
- Wann (2011) Circulation 123(1): 104-23 [PubMed]